Standout Papers

Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis 2017 2026 2020 2023 382
  1. Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis (2017)
    Kim Papp, Andrew Blauvelt et al. New England Journal of Medicine

Immediate Impact

6 by Nobel laureates 33 from Science/Nature 66 standout
Sub-graph 1 of 20

Citing Papers

Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis
2021 Standout
A role of PIEZO1 in iron metabolism in mice and humans
2021 StandoutNobel
22 intermediate papers

Works of Paul Scholl being referenced

Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study
2018
Protein tyrosine phosphorylation induced via the IgG receptors Fc gamma Ri and Fc gamma RII in the human monocytic cell line THP-1
1992
and 2 more

Author Peers

Author Last Decade Papers Cites
Paul Scholl 1882 289 264 346 327 37 2.4k
S Hudak 1906 589 358 223 178 33 3.2k
Pierre Garrone 2610 594 196 201 285 33 3.5k
Joyce Eskdale 1817 443 115 184 489 46 3.0k
K. I. Welsh 1604 438 334 169 500 77 3.3k
Fabio Almerigogna 1814 359 291 228 185 61 2.9k
Kazimiera J. Gajl‐Peczalska 890 310 202 195 150 40 3.1k
Ikuya Tsuge 1552 284 57 302 199 86 2.9k
Wolfgang Dummer 2706 447 354 578 496 56 3.8k
J. Alero Thomas 1193 432 306 171 150 57 3.0k
François Fossiez 2751 509 126 395 485 23 3.8k

All Works

Loading papers...

Rankless by CCL
2026